Extracellular vesicles reflect the biology of the cell that released them. Two products both described as exosomes can differ substantially if one is derived from a specific progenitor cell line grown under defined culture conditions and the other is isolated directly from a donated fluid such as cord blood, because the surface markers and internal cargo reported on a characterization panel trace back to the source cell.
If available, source cell documentation should cover what type of cell or cell line was used, how it was obtained and banked, and what quality steps were applied to the cell population before vesicles were harvested from it. This is a separate record from the vesicle characterization data itself, which covers testing such as ELISA, nanoparticle tracking analysis, or marker panels, even though both describe the same finished product.
Buyers comparing exosome products from different suppliers should ask for the source cell description as part of the supplier's documentation package, alongside the vesicle characterization data, since the two together describe what the product is and how it was made.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice. FDA has stated no exosome product carries FDA approval. Exosome products are generally regulated as biologic drugs under section 351, and the decision to purchase or use one clinically rests with the physician and their regulatory counsel.
Source cell documentation helps a clinic understand what a product is derived from, which is part of building a complete vendor qualification file.